TABLE 4.
Antifungal susceptibility and MIC distribution of 110 Cryptococcus strains in a tertiary hospital in mainland China.
| VNI (105) |
VGII (4) |
VNIV (1) |
|||||||||||
| ECV | WT | Non-WT | MIC50 (mg/L) | MIC90 (mg/L) | Range (mg/L) | ECV | WT | Non-WT | MIC50 (mg/L) | MIC90 (mg/L) | Range (mg/L) | MIC (mg/L) | |
| Fluconazole | 8 | 96 (91.4%) | 9 (8.6%) | 4 | 8 | 1.0–64.0 | 32 | 4 (100%) | 0 | 8 | 16 | 4.0–16.0 | 8 |
| 5-Fluorocytosine | 8 | 98 (93.3%) | 7 (6.6%) | 4 | 8 | 1.0–64.0 | 32 | 4 (100%) | 0 | 4 | 4 | 2.0–4.0 | 4 |
| Amphotericin B | 0.5 | 96 (91.4%) | 9 (8.6%) | 0.5 | 0.5 | 0.12–2.0 | 1 | 4 (100%) | 0 | 0.25 | 0.5 | 0.25–0.5 | 0.5 |
| Posaconazole | 0.25 | 101 (96.2%) | 4 (3.8%) | 0.12 | 0.25 | 0.03–0.5 | NA | NA | NA | 0.12 | 0.25 | 0.12–0.25 | 0.5 |
| Itraconazole | 0.25 | 105 (99.0%) | 1 (1.0%) | 0.06 | 0.12 | 0.015–0.5 | 1 | 4 (100%) | 0 | 0.06 | 0.25 | 0.06–0.25 | 0.25 |
| Voriconazole | 0.25 | 105 (100%) | 0 | 0.06 | 0.12 | 0.015–0.25 | 0.5 | 4 (100%) | 0 | 0.06 | 0.25 | 0.03–0.25 | 0.12 |
MIC, minimum inhibitory concentration; WT, wild-type; Non-WT, non-wild-type; ECV, the epidemiologic cutoff value; NA, not available; MIC50, the minimum inhibitory concentration at which 50% of isolates were inhibited; MIC90, the minimum inhibitory concentration at which 90% of isolates were inhibited; MIC range, range of minimum inhibitory concentration.